KRAS and neoplasm: Importantly, among tumours with at least three driver mutations, a similar number of tumours with alternative combinations of drivers to the classical CRC combination (APC, KRAS, TP53) (Fearon and Vogelstein, 1990) were observed (45 and 39%, respectively) (Fig. 1F).